PerkinElmer Prices Offering of Senior Notes

Rhea-AI Summary

PerkinElmer (NYSE: PKI) has priced a $400 million offering of 2.550% Senior Notes due 2031 and 3.625% Senior Notes due 2051. The offering, expected to close on March 8, 2021, aims to utilize approximately $561 million of net proceeds to repay debt related to its acquisition of Oxford Immunotec Global PLC and to refinance existing senior notes. This strategic move aligns with the company's focus on innovation and maintaining a healthy financial position.

Positive

• The issuance of notes will help finance the acquisition of Oxford Immunotec, potentially expanding PerkinElmer's market capabilities.
• Proceeds will be used to repay a portion of existing debt, improving the company’s balance sheet.

Negative

• No immediate negative aspects noted.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of $400.0 million aggregate principal amount of 2.550% Senior Notes due 2031 at an issue price of 99.965% of the principal amount and $400.0 million aggregate principal amount of 3.625% Senior Notes due 2051 at an issue price of 99.999% of the principal amount.

The issuance of the notes is expected to close on March 8, 2021, subject to customary closing conditions. The notes will pay interest on a semi-annual basis.

PerkinElmer plans to use approximately $561 million of the net proceeds of the offering to repay amounts borrowed under its senior unsecured revolving credit facility to fund a portion of the purchase price for its acquisition of Oxford Immunotec Global PLC. PerkinElmer expects to use the remaining net proceeds of the offering to repay at maturity a portion of its outstanding €300.0 million aggregate principal amount of 0.600% senior notes due 2021.

The joint book-running managers for the offering are J.P. Morgan Securities LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC.

The offering is being made pursuant to an effective registration statement on Form S-3 (including a prospectus) filed with the U.S. Securities and Exchange Commission (“SEC”). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the offering and the other documents that PerkinElmer has filed with the SEC for more complete information about the company and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus relating to the offering can be obtained by calling one of the joint book-running managers at the following: J.P. Morgan Securities LLC collect at 1-212-834-4533 or BofA Securities, Inc. toll-free at 1-800-294-1322.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $3.8 billion in 2020, has about 14,000 employees serving customers in more than 190 countries, and is a component of the S&P 500 Index.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about PerkinElmer’s intended use of proceeds, including its acquisition of Oxford Immunotec Global PLC. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the offering. Additional important factors and information regarding PerkinElmer’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the prospectus and preliminary prospectus supplement dated March 4, 2021 related to the offering, which is on file with the SEC and available in the “Investors” section of the Company’s website under the heading “SEC Filings,” and the documents incorporated by reference into the prospectus and prospectus supplement. While PerkinElmer may elect to update forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to today.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006173/en/

FAQ

What are the details of PerkinElmer's recent bond offering?

PerkinElmer is offering $400 million of 2.550% Senior Notes due 2031 and $400 million of 3.625% Senior Notes due 2051, closing on March 8, 2021.

How will PerkinElmer use the proceeds from the bond offering?

Approximately $561 million will be used to repay debt related to the acquisition of Oxford Immunotec and to refinance a portion of existing senior notes.

What is the impact of PerkinElmer's bond offering on shareholder value?

The bond offering is expected to strengthen PerkinElmer's financial position by reducing debt and funding strategic acquisitions.